Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries

Celso Arango(Hospital Universitario La Paz), Jannie van der Westhuizen, Igor Martsenkovsky(Ministry of Internal Affairs of the Republic of Tajikistan), Gert P Bosch, Ellina Melnyk, Jan K. Buitelaar(Radboud University Nijmegen), Олег Чабан, Elena Predescu(Iuliu Hațieganu University of Medicine and Pharmacy), O.A. Bukhanovskaya, Magdolna Gácser, Juan Schronen(Health & Medical Publishing Group), A. M. Skrypnikov, Péter Nagy(Vadaskert Alapítvány a Gyermekek Lelki Egészségéért), J. Barylnik, Bruno Falissard(Inserm), Laura Birdeanu, Pierre‐François Pénélaud(Servier (France)), Damien Chimits(Servier (France)), Ute C. Marx(Servier (France)), Svetlana Ivanović-Kovačević, Enikõ Bugán, Tetiana Matkovska, Dejan Stevanović, Laura Alexandra Nussbaum(Victor Babeș University of Medicine and Pharmacy Timișoara), Valérie Olivier(Servier (France)), Halina Flisiak-Antonijczuk, Markku Timonen, Igor Boyev, Gábor Feller, O.P. Mostova, Krisztina Kapornai(University of Szeged), Petar Petrov(Agennix (United States)), Mirela Matican, Miodrag Stanković, Nadia Polnareva, Timo Holttinen, Л.Н. Касимова, N. Maruta(Institute of Neurology, Psychiatry and Narcology), Julia Boychevskaya, Jörg M. Fegert(Universität Ulm), Dmitrii Shigashov, Vladislava Razsolkova, Milica Pejović-Milovančević(Queen's University), Filip Rybakowski(Essen University Hospital), Sofiia Rymsha, Iuliana Dobrescu, Juha-Matti Väänänen, Bożena Pietraszczyk-Kędziora, Evgeniy Koren, E.A. Grigorieva
The Lancet Psychiatry
December 14, 2021
Cited by 33


Related Papers